Online citations, reference lists, and bibliographies.
← Back to Search

Human Enteric Microsomal CYP4F Enzymes O-Demethylate The Antiparasitic Prodrug Pafuramidine

M. Z. Wang, J. Q. Wu, A. S. Bridges, D. Zeldin, S. Kornbluth, R. Tidwell, J. Hall, M. Paine
Published 2007 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
CYP4F enzymes, including CYP4F2 and CYP4F3B, were recently shown to be the major enzymes catalyzing the initial oxidative O-demethylation of the antiparasitic prodrug pafuramidine (DB289) by human liver microsomes. As suggested by a low oral bioavailability, DB289 could undergo first-pass biotransformation in the intestine, as well as in the liver. Using human intestinal microsomes (HIM), we characterized the enteric enzymes that catalyze the initial O-demethylation of DB289 to the intermediate metabolite, M1. M1 formation in HIM was catalyzed by cytochrome P450 (P450) enzymes, as evidenced by potent inhibition by 1-aminobenzotriazole and the requirement for NADPH. Apparent Km and Vmax values ranged from 0.6 to 2.4 μM and from 0.02 to 0.89 nmol/min/mg protein, respectively (n = 9). Of the P450 chemical inhibitors evaluated, ketoconazole was the most potent, inhibiting M1 formation by 66%. Two inhibitors of P450-mediated arachidonic acid metabolism, HET0016 (N-hydroxy-N′-(4-n-butyl-2-methylphenyl)formamidine) and 17-octadecynoic acid, inhibited M1 formation in a concentration-dependent manner (up to 95%). Immunoinhibition with an antibody raised against CYP4F2 showed concentration-dependent inhibition of M1 formation (up to 92%), whereas antibodies against CYP3A4/5 and CYP2J2 had negligible to modest effects. M1 formation rates correlated strongly with arachidonic acid ω-hydroxylation rates (r2 = 0.94, P < 0.0001, n = 12) in a panel of HIM that lacked detectable CYP4A11 protein expression. Quantitative Western blot analysis revealed appreciable CYP4F expression in these HIM, with a mean (range) of 7 (3-18) pmol/mg protein. We conclude that enteric CYP4F enzymes could play a role in the first-pass biotransformation of DB289 and other xenobiotics.
This paper references
10.1021/BI962359Z
Cooperativity in oxidations catalyzed by cytochrome P450 3A4.
Y. Ueng (1997)
10.1124/MOL.104.004150
Enhancement of Cardiac L-Type Ca2+ Currents in Transgenic Mice with Cardiac-Specific Overexpression of CYP2J2
Y. Xiao (2004)
Activation of CYP 3 A 4 : evidence for the simultaneous binding of two substrates in a cytochrome P 450 active site
M Shou (1994)
10.1002/JMS.591
Metabolites of an orally active antimicrobial prodrug, 2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime, identified by liquid chromatography/tandem mass spectrometry.
Lian Zhou (2004)
10.1111/j.1749-6632.1990.tb17862.x
Development of Pentamidine Analogues as New Agents for the Treatment of Pneumocystis carinii Pneumonia a
R. Tidwell (1990)
Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation.
D. Kroetz (2005)
Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11.
P. Powell (1998)
10.1152/AJPHEART.00924.2001
20-HETE contributes to the acute fall in cerebral blood flow after subarachnoid hemorrhage in the rat.
F. Kehl (2002)
10.1006/BBRC.2000.4238
cDNA cloning and expression of a novel cytochrome p450 (cyp4f12) from human small intestine.
T. Hashizume (2001)
10.1124/dmd.105.008672
THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
M. Paine (2006)
10.1021/BI00187A009
Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site.
M. Shou (1994)
10.1016/J.PHARMTHERA.2006.03.008
Cytochrome P450 4F subfamily: at the crossroads of eicosanoid and drug metabolism.
A. Kalsotra (2006)
10.1016/S0960-894X(96)00557-4
Anti-pneumocystis activity of bis-amidoximes and bis-o-alkylamidoximes prodrugs
D. Boykin (1996)
10.1146/ANNUREV.PHARMTOX.45.120403.100045
REGULATION AND INHIBITION OF ARACHIDONIC ACID ω-HYDROXYLASES AND 20-HETE FORMATION
D. Kroetz (2005)
Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol.
R. Obach (1997)
10.1124/DMD.32.1.105
Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible.
D. Stresser (2004)
10.1124/JPET.300.1.298
Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes.
T. Hashizume (2002)
10.1124/JPET.103.059626
Catalytic Activity and Isoform-Specific Inhibition of Rat Cytochrome P450 4F Enzymes
F. Xu (2004)
10.1038/sj.bjp.0707354
Human African trypanosomiasis: pharmacological re‐engagement with a neglected disease
M. Barrett (2007)
10.1152/ajpregu.1999.276.6.R1691
Kinetic profile of the rat CYP4A isoforms: arachidonic acid metabolism and isoform-specific inhibitors.
X. Nguyen (1999)
10.1124/MOL.61.4.840
Cloning of CYP2J2 gene and identification of functional polymorphisms.
Lorraine M. King (2002)
10.1023/A:1020957430400
Enhanced Permeability of the Antimicrobial Agent 2,5-Bis(4-Amidinophenyl)Furan Across Caco-2 Cell Monolayers Via Its Methylamidoxime Prodrug
Lian Zhou (2004)
Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(Nmethoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug
I Midgley (2007)
10.1124/dmd.106.013391
Pharmacokinetics and Metabolism of the Prodrug DB289 (2,5-Bis[4-(N-methoxyamidino)phenyl]furan Monomaleate) in Rat and Monkey and Its Conversion to the Antiprotozoal/Antifungal Drug DB75 (2,5-Bis(4-guanylphenyl)furan Dihydrochloride)
I. Midgley (2007)
10.1021/JM00214A014
Synthesis and antiprotozoal activity of 2,5-bis(4-guanylphenyl)furans.
B. P. Das (1977)
Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole.
M. Paine (1999)
10.1128/AAC.34.7.1381
Structure-activity relationships of analogs of pentamidine against Plasmodium falciparum and Leishmania mexicana amazonensis.
C. Bell (1990)
Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase.
D. Zeldin (1993)
Diamidines as antitrypanosomal, antileishmanial and antimalarial agents.
K. Werbovetz (2006)
10.1074/JBC.M104818200
Alternative splicing determines the function of CYP4F3 by switching substrate specificity.
P. Christmas (2001)
10.1124/dmd.105.005017
UNUSUAL DEHYDROXYLATION OF ANTIMICROBIAL AMIDOXIME PRODRUGS BY CYTOCHROME b5 AND NADH CYTOCHROME b5 REDUCTASE
Janelle Y Saulter (2005)
10.1016/0001-706X(93)90090-X
Human trypanosomiasis in the Ivory Coast: therapy and problems.
F. Doua (1993)
10.1124/dmd.106.010587
CYP4F Enzymes Are the Major Enzymes in Human Liver Microsomes That Catalyze the O-Demethylation of the Antiparasitic Prodrug DB289 [2,5-Bis(4-amidinophenyl)furan-bis-O-methylamidoxime]
M. Z. Wang (2006)
10.1074/jbc.272.6.3149
Differential Mechanisms of Cytochrome P450 Inhibition and Activation by α-Naphthoflavone*
A. P. Koley (1997)



This paper is referenced by
10.3390/tropicalmed5010029
New Drugs for Human African Trypanosomiasis: A Twenty First Century Success Story
Emily A Dickie (2020)
10.1124/dmd.116.070367
A New Marmoset P450 4F12 Enzyme Expressed in Small Intestines and Livers Efficiently Metabolizes Antihistaminic Drug Ebastine
S. Uehara (2016)
10.1055/s-0030-1250259
Isolation and identification of intestinal CYP3A inhibitors from cranberry (Vaccinium macrocarpon) using human intestinal microsomes.
Eunkyung Kim (2011)
10.1248/bpb.b16-00370
Evaluation of CYP2D6 Protein Expression and Activity in the Small Intestine to Determine Its Metabolic Capability in the Japanese Population.
Momoko Kawakami (2017)
10.3389/fphys.2010.00014
Biochemistry and Occurrence of O-Demethylation in Plant Metabolism
J. Hagel (2010)
10.1124/dmd.108.024968
Identification of a Cranberry Juice Product that Inhibits Enteric CYP3A-Mediated First-Pass Metabolism in Humans
N. Ngo (2009)
Reduktion N-oxygenierter Verbindungen durch die mitochondriale Amidoxim Reduzierende Komponente (mARC)
Danilo Froriep (2013)
Translational methods for quantitative prediction of metabolic herbal product-drug interactions: case study with milk thistle
Scott J. Brantley (2013)
10.1016/B978-0-08-046884-6.00844-7
10.05 – Metabolic Barrier of the Gastrointestinal Tract*
K. Wolf (2010)
Effects of parasitic infection on the pharmacokinetics and disposition of pentamidine analogs
Claudia N Generaux (2010)
10.2133/dmpk.DMPK-10-SH-119
Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans.
H. Nishimuta (2011)
10.3109/00498254.2014.952800
Immunochemical quantification of cynomolgus CYP2J2, CYP4A and CYP4F enzymes in liver and small intestine
S. Uehara (2015)
Detection and Mechanistic Comparison of Two Anti- Trypanosomal Diamidines in a Rat Renal Model
R. B. Goldsmith (2011)
10.1007/s40262-015-0351-6
Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models
S. Peters (2016)
Determination of Absolute Protein Content of Hepatic CYP4F Enzymes in Human Liver Microsomes Using LC/MS/MS Methodology and Comparison with Immunoquantification and Enzyme Activity
Scott A. Michaels (2013)
10.4155/FMC.12.197
Cytochrome P450-activated prodrugs.
P. R. Montellano (2013)
10.1002/jcph.1444
Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K1
J. Park (2019)
10.3389/fphar.2017.00323
Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response
J. E. Zhang (2017)
10.1124/dmd.112.047134
Impact of Organic Solvents on Cytochrome P450 Probe Reactions: Filling the Gap with (S)-Warfarin and Midazolam Hydroxylation
Vanessa González-Pérez (2012)
10.1097/FPC.0000000000000100
PharmGKB summary: very important pharmacogene information for CYP4F2
Maria L Alvarellos (2015)
10.1128/AAC.02309-13
In Vitro and In Vivo Evaluation of 28DAP010, a Novel Diamidine for Treatment of Second-Stage African Sleeping Sickness
T. Wenzler (2014)
10.1515/dmdi-2011-0037
Human cytochrome P450 4F3: structure, functions, and prospects
L. Corcos (2012)
10.1039/c0ob01117g
Prodrug design for the potent cardiovascular agent Nω-hydroxy-L-arginine (NOHA): synthetic approaches and physicochemical characterization.
D. Schade (2011)
10.3390/molecules23051195
Involvement of CYP4F2 in the Metabolism of a Novel Monophosphate Ester Prodrug of Gemcitabine and Its Interaction Potential In Vitro
Yedong Wang (2018)
10.1124/dmd.110.035378
CYP4F Enzymes Are Responsible for the Elimination of Fingolimod (FTY720), a Novel Treatment of Relapsing Multiple Sclerosis
Y. Jin (2011)
10.1124/dmd.113.052563
A Systematic Approach to Evaluate Herb-Drug Interaction Mechanisms: Investigation of Milk Thistle Extracts and Eight Isolated Constituents as CYP3A Inhibitors
S. Brantley (2013)
10.4155/fmc.12.197
Cytochrome P450-activated prodrugs.
P. R. Ortiz de Montellano (2013)
Développement de méthodes analytiques par LC-MS/MS pour la caractérisation de l’activité et de l’expression des CYP450s chez l’humain
Alexia Grangeon (2017)
10.3109/00498254.2014.895882
Immunochemical detection of cytochrome P450 enzymes in small intestine microsomes of male and female untreated juvenile cynomolgus monkeys
S. Uehara (2014)
10.1124/dmd.111.040063
A Semiphysiologically Based Pharmacokinetic Modeling Approach to Predict the Dose-Exposure Relationship of an Antiparasitic Prodrug/Active Metabolite Pair
Grace Zhixia Yan (2012)
10.1002/cmdc.201100422
New Prodrugs of the Antiprotozoal Drug Pentamidine
Joscha Kotthaus (2011)
10.1016/j.jpba.2019.05.006
Development and validation of an absolute protein assay for the simultaneous quantification of fourteen CYP450s in human microsomes by HPLC-MS/MS-based targeted proteomics.
Alexia Grangeon (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar